Clinical trials
Lung Cancer (Locally Advanced or Metastatic) clinical trials
Below are recruiting lung cancer (locally advanced or metastatic) clinical trials, each written for real people, not researchers. We’re tracking 5,800 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07619235RecruitingPhase 4
Combination immunotherapy and chemotherapy for advanced bile duct cancer
This study tests a combination of four drugs—two immunotherapy drugs (iparomlimab and toripalimab), a targeted therapy (bevacizumab), and chemotherapy—as a first-line treatment for advanced biliary tract cancer (cancer of the bile ducts or gallbladder). The goal is to see if this combination can shrink tumors and help patients live longer.
Wuhan, HubeiAges 18–75 - NCT07614061RecruitingPhase 1
Cell therapy for advanced bile duct cancer
This trial tests a new treatment called BTC-Ag-T, which uses your own immune cells enhanced in the lab to fight advanced biliary tract cancer (cancer of the bile ducts or gallbladder). It's designed for patients whose cancer has spread or cannot be surgically removed and who have already received standard chemotherapy plus immunotherapy.
ShanghaiAges 18 years+ - NCT03860883Recruiting
Comparing wider versus narrower surgery margins for stage II melanoma
This trial studies whether removing a slightly wider strip of skin around a melanoma improves outcomes compared with a narrower strip. It also uses a lymph node staging procedure to check spread and helps doctors fine-tune surgery for stage II melanoma.
Mobile, AlabamaAges 18 years+ - NCT06706921RecruitingPhase 4
Predicting treatment success with PET scans in prostate cancer
This study looks at whether a special PET scan can help predict how well a targeted radiation therapy (LuPSMA) works in men with advanced prostate cancer that has spread. You would get several PET scans before and after treatment to see if the scan results can forecast your outcome.
Los Angeles, CaliforniaAges 18 years+ - NCT07608835Recruiting
Lung Cancer Biomarkers and Immune Treatment Study
This study looks for biological markers (special signs in your body) that could help doctors choose better immune-based treatments for non-small cell lung cancer. Researchers will study your tumor and blood to understand which patients might benefit most from immunotherapy.
Marseille, Institut Paoli CalmettesAges 18 years+ - NCT07612215RecruitingPhase 1/Phase 2
Elacestrant for Advanced Triple-Positive Breast Cancer
This trial tests a new drug called elacestrant for advanced breast cancer that is triple-positive (positive for three hormone receptors: ER, PR, and HER2). The drug may help slow or shrink cancer that has progressed despite previous treatments.
New York, New YorkAges 18 years+ - NCT06711471RecruitingPhase 2
Combination therapy for advanced stomach cancer after prior treatments
This trial tests a combination of three drugs — trifluridine/tipiracil (a chemotherapy pill), bevacizumab (avastin, a targeted therapy), and camrelizumab (an immunotherapy) — as a later treatment option for people with advanced stomach cancer who have already tried other therapies. It may help patients whose cancer has not responded to previous treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07597993Recruiting
Real-world study of Trastuzumab Deruxtecan for advanced breast cancer
This study follows women with advanced breast cancer (metastatic) who have hormone-receptor positive tumors and low HER2 levels, to see how well a new drug called Trastuzumab Deruxtecan works when used in routine clinical care after prior hormone therapy.
MuscatAges 18 years+ - NCT06718738RecruitingPhase 1
IM96 CAR-T for advanced colorectal cancer
This trial tests a new cell therapy called IM96 CAR-T, which targets a protein (GUCY2C) found on tumor cells. It is for people with advanced colorectal or stomach cancer that has not responded to standard treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT07589530RecruitingPhase 1/Phase 2
CAR NK Cell Therapy for Advanced Solid Tumors
This study tests a new immune cell treatment called EB-NK-301, which are lab-modified natural killer cells designed to attack cancer cells that have a protein called TROP2. The trial is for people with advanced solid tumors (cancers that have spread) whose cancer has stopped responding to standard treatments.
Shenzhen, GuangdongAges 18–75 - NCT07587216Recruiting
Liver Cancer Patient Database Study
This study builds a database of information from liver cancer patients treated at Tongji Hospital. Researchers will collect your medical records and treatment information to better understand liver cancer diagnosis and care over time.
Wuhan, HubeiAges 18 years+ - NCT07584954RecruitingPhase 1
Testing a new cancer immunotherapy in advanced solid tumors
This Phase 1 trial tests a new drug called IUAb190708 designed to help your immune system fight advanced or recurrent solid cancers. The study will evaluate its safety, how your body handles it, and whether it works against your tumor.
Fuzhou, FujianAges 18–75 - NCT07583485Recruiting
Tucatinib combination therapy for advanced HER2-positive breast cancer
This study watches how well a three-drug combination (tucatinib, capecitabine, and trastuzumab) works for women with breast cancer that has spread to other parts of the body and has a protein called HER2. You'll be treated as you normally would be in a clinic, and researchers will track how you respond.
Avellino, AVAges 18 years+ - NCT06728189RecruitingPhase 1
CD70-targeted CAR-NKT cells for advanced solid tumors
This trial tests a new type of immune cell therapy (CAR-NKT cells) that targets a protein called CD70 on cancer cells. It is for people with advanced solid tumors that have not responded to at least two prior treatments.
BeijingAges 18–75 - NCT07559786RecruitingPhase 2
Adebrelimab after chemo-radiation for limited-stage small cell lung cancer
This trial tests whether the drug adebrelimab (a type of immunotherapy) can help prevent your lung cancer from coming back after you finish chemotherapy and radiation. It is for people with limited-stage small cell lung cancer (cancer found only in one lung and nearby lymph nodes) that did not grow during initial treatment.
Zhengzhou, HenanAges 18–75 - NCT04170634Recruiting
CT scan study to assess bone strength in certain cancers
This study uses a CT scan to estimate how strong a cancer-affected bone area is, helping doctors evaluate fracture risk and bone management. It is aimed at adults with bone lesions from several common cancer types.
AngersAges 18 years+ - NCT05859750RecruitingPhase 2
AK104 plus chemotherapy for advanced pancreatic cancer
This trial tests AK104 (an antibody medicine) given with standard chemotherapy as the first treatment for advanced pancreatic ductal cancer. It aims to see whether this combination works better and is safe for people with cancer that has spread or is advanced.
Beijing, Beijing MunicipalityAges 18–75 - NCT07562438RecruitingPhase 2
Lutetium-177 Treatment for Advanced Prostate Cancer
This trial tests a radioactive medication (177Lu-P17-088) designed to target and treat prostate cancer that has spread to other parts of the body and stopped responding to hormone therapy. The medication is guided to cancer cells using a special imaging scan, potentially offering a new treatment option for men who have already tried other standard therapies.
Fuzhou, FujianAges 18–90 - NCT06738459Recruiting
Matching lymph node tests in breast cancer
This study looks back at past MRI scans and lymph node biopsies or surgeries in people with breast cancer to better understand how cancer spreads to the lymph nodes. If you had these tests as part of your care, your data might help improve future treatment decisions.
VillachAges 18 years+ - NCT07557251RecruitingPhase 1
Combination immunotherapy for advanced liver cancer with hepatitis B
This trial tests a new combination of three drugs (BRII-5395, sintilimab, and bevacizumab) for advanced hepatocellular carcinoma (liver cancer) in patients with hepatitis B who have not responded well to previous treatments. The goal is to evaluate whether this combination is safe and effective.
BeijingAges 18–70 - NCT07558083RecruitingPhase 3
Tracking colorectal cancer response using blood tests
This study tests whether a simple blood test can track how well your colorectal cancer is responding to first-line chemotherapy. By monitoring cancer markers in your blood, doctors may be able to detect treatment changes earlier than traditional imaging.
Mechelen, AntwerpenAges 18 years+ - NCT07544589RecruitingPhase 1
Study of DISP-10 for advanced gastrointestinal cancers
This trial tests a new treatment called DISP-10 for people with advanced cancers of the digestive system, such as stomach, colon, or bile duct cancers. It aims to see if DISP-10 is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT07544654RecruitingPhase 3
Study comparing obrixtamig plus chemotherapy for advanced neuroendocrine cancer
This trial tests a new drug called obrixtamig combined with standard chemotherapy for advanced neuroendocrine cancer (a rare type of cancer). You'd receive one cycle of standard chemotherapy first, then be randomly assigned to either continue with the new drug plus chemotherapy or standard chemotherapy alone.
Scottsdale, ArizonaAges 18 years+ - NCT07551349RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Kidney Cancer
This trial tests a new type of cell therapy (CAR-NK cells) designed to target kidney cancer that has spread or cannot be removed with surgery. The cells are engineered in the lab to recognize and attack cancer cells, and may help patients whose cancer has grown despite previous treatments.
Shenzhen, GuangdongAges 18 years+
Hear when a new Lung Cancer (Locally Advanced or Metastatic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer (locally advanced or metastatic)?
- Yes. Clin2 currently lists 5,800 recruiting lung cancer (locally advanced or metastatic) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer (locally advanced or metastatic) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer (locally advanced or metastatic) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced Non-Small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Colorectal Cancer (Locally Advanced or Metastatic)
- Liver Cancer (Locally Advanced or Metastatic)
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.